Envision Report

Published January 11, 2018

Biopharmaceuticals Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Download Free Sample Report!

Biopharmaceuticals are pharmaceutical products which are produced through biotechnology methods involving recombinant DNA techniques, hybridoma techniques, and purification processes. Biopharmaceutical production consists of the use of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.

Biopharmaceuticals Market Segments Size & Growth:

Biopharmaceuticals market size is projected to reach approximately $294 billion by the end of 2024 with a CAGR of close to 8.9% from $178 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include High-profit margins, Huge market demand, Ability of Biopharmaceuticals to treat previously untreatable diseases, Increasing acceptance for Biopharmaceuticals and so on. However, High-end manufacturing requirements, Increasing demand for affordable Biopharmaceuticals and Complicated and Cumbersome regulatory requirements are thereby hampering the market growth.

Biopharmaceuticals Market Segments Share:

Biopharmaceuticals Market is categorised into a type which comprises of Monoclonal antibodies, Recombinant growth factors, Purified proteins, Recombinant proteins, Recombinant hormones and so on. Among the Type, a Monoclonal antibodies market segment dominated the Biopharmaceuticals market in 2018 with about 25.9% share. By Therapeutic Applications, Biopharmaceuticals market is segregated into Neurological diseases, Cardiovascular diseases, Hormonal disorders and so on. Among the Therapeutic Applications, Oncology segment is projected to continue its dominant during the period 2018-2024. By Geography, North America is expected to dominate the Biopharmaceuticals market and the growth in the North America economies is mainly attributed because of huge profit margins and growth prospects, biopharmaceuticals have garnered the attention of several large drug development companies.

Biopharmaceuticals Market Trends:

  • Biopharmaceuticals currently represent a large segment of product pipelines of most of the major pharmaceutical companies.
  • Monoclonal antibodies currently own the most significant market share regarding value in the global biopharmaceuticals market. Some of the top-selling monoclonal antibodies include Adalimumab, Infliximab, Rituximab, and Bevacizumab.
  • Pfizer and Wyeth announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $69 billion.

Biopharmaceuticals Market Research Report:

  • An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
  • To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
  • Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
  • Identifying DROC in the current market and their impact in altering the market dynamics.
  • Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
  • Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
  • The primary market players, such as
  • Pfizer
  • Novo Nordisk
  • Merck & Co
  • Johnson & Johnson
  • Bristol Myers Squibb

Chapter 1 Introduction

1.1 Executive Summary

1.2 Market Definition

1.3 Scope of  the Study

Chapter 2 Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.3 Analytic Tools and Model

2.4 Economic Indicator

2.4.1 Base Year, Base Currency, Forecasting Period

2.5 Expert Validation

2.6 Study Timeline

Chapter 3 Market Analysis

3.1 Industry Value Chain Analysis

3.2 Porter’s Five Analysis

3.2.1 Bargaining Power of Buyers

3.2.2 Bargaining Power of Suppliers

3.2.3 Threats of Substitutes

3.2.4 Threats of New Entrants

3.2.5 Industry Rivalry

3.3 PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4 SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threat

3.5 Y-O-Y Analyses

Chapter 4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5 Market Segmentation Analysis        

Chapter 6 Market Segmentation, By Type

     6.1 Monoclonal Antibodies

6.1.1 Anti-Inflammatory Monoclonal Antibodies

6.1.2 Anti-Cancer Monoclonal Antibodies

6.1.3 Other Monoclonal Antibodies

6.2 Recombinant Growth Factors

6.2.1 Granulocyte Colony Stimulating Factor

6.2.2 Erythropoietin

6.3 Purified Proteins

6.3.1 P53 Protein

6.3.2 P38 Protein

6.3.3 Leukemia Inhibitory Factor (LIF)

6.4 Recombinant Proteins

6.4.1 Cathepsin

6.4.2 Caspase

6.4.3 Cyclase

6.4.4 Defensin

6.4.6 Amyloid Protein

6.4.7 Serum Albumin

6.5 Recombinant Hormones

6.5.1 Recombinant Insulin

6.5.2 Recombinant Human Growth Hormone (HGH)

6.6 Synthetic Immunomodulators

6.6.1 Tumor Necrosis Factor (TNF)

6.6.2 Cytokines, Interferons, Interleukins

6.7 Vaccines

6.7.1 Recombinant Vaccines

6.7.1.1 Cholera Vaccine

6.7.1.2 Diphtheria Vaccine

6.7.1.3 Tetanus vaccine

6.7.1.4 Hepatitis-B Vaccine

6.7.1.5 Ebola Vaccine

6.7.1.6 Malaria Vaccine

6.7.1.7 Cancer Vaccines

6.7.2 Conventional Vaccines

6.7.2.1 Pox Vaccine

6.7.2.2 Polio Vaccine

6.8 Recombinant Enzymes

6.8.1 Transferrin

6.8.2 Enterokinase

6.9 Others

Chapter 7 Market Segmentation, By Therapeutic Applications

     7.1 Neurological Diseases

7.2 Cardiovascular Diseases

7.3 Disease Prevention

7.4 Hormonal Disorders

7.5 Metabolic Disorders

7.6 Autoimmune Disorders

7.7 Inflammatory and Infectious Diseases

7.8 Oncology

7.9 Other Diseases

Chapter 8 Market Segmentation, By Geography

     8.1 North America

8.1.1 Introduction

8.1.2 United States

8.1.3 Canada

8.1.4 Mexico

8.1.5 Others

8.2 Europe

8.2.1 Introduction

8.2.2 U.K

8.2.3 Spain

8.2.4 Italy

8.2.5 France

8.2.6 Russia

8.2.7 Others

8.3 Asia-Pacific

8.3.1 Introduction

8.3.2 China

8.3.3 India

8.3.4 Japan

8.3.5 Australia & New Zealand

8.3.6 Others

8.4 South  America

8.4.1 Introduction

8.4.2 Brazil

8.4.3 Argentina

8.4.4 Others

8.5 The Middle East & Africa

8.5.1 Introduction

8.5.2 South Africa

8.5.3 Others

Chapter 9 Competitive Landscape

9.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements

9.2  Market Share Analysis

9.3 Strategies Adopted By Top Companies

Chapter 10 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

10.1. Takeda

10.1.1. Company Overview

10.1.2. Financial Performance

10.1.3. Product Benchmarking

10.1.4. Strategic Initiative

10.2. Sanofi Aventis

10.3. Roche

10.4. Regeneron

10.5. Pfizer

10.6. Novo Nordisk

10.7. Novartis

10.8. Merck & Co

10.9. Johnson & Johnson

10.10. Genentech

10.11. Bristol Myers Squibb

10.12. Biogen

10.13. Bayer

10.14. Amgen

10.15. AbbVie

Chapter 11 Market Estimates and Forecast

11.1   Market Estimates and Forecast 2018-2024(USD Million)

11.1.1 Market Estimation and Forecast by Type 2018-2024 (USD Million)

11.1.1 Market Estimation and Forecast by Therapeutic Applications 2018-2024 (USD Million)

11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)

Chapter 12 Market Insights

12.1 Insights of Industry Experts

12.2 Analyst Opinion (Market Understanding)

12.3 Investment Opportunities

Chapter 13 Appendix

13.1 List of Tables

13.2 List of Figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.

 

©2018 - Envision Inteligence | All Rights Reserved.